Cargando…
Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2− Breast Cancer Patient With High Tumor Mutational Burden
Endocrine treatment plus CDK4/6 inhibitors have become standard of care for estrogen receptor positive (ER+) breast cancer. Although immune checkpoint inhibitors (ICIs) have shown promising antitumor activity in a variety of cancer types, only limited success has been achieved for metastatic breast...
Autores principales: | Wang, Rong, Yang, Yuchen, Ye, Wei-Wu, Xiang, Jianxing, Chen, Songan, Zou, Wei-Bin, Wang, Xiao-Jia, Chen, Tianhui, Cao, Wen-Ming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900143/ https://www.ncbi.nlm.nih.gov/pubmed/33634015 http://dx.doi.org/10.3389/fonc.2020.588080 |
Ejemplares similares
-
Efficacy of Pyrotinib in a Heavily Pretreated Patient with Lung Adenocarcinoma Harboring HER2 Amplification and Exon 20 Insertions: A Case Report
por: Shan, Jianzhen, et al.
Publicado: (2020) -
Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer
por: Liu, Jieqiong, et al.
Publicado: (2022) -
Case Report: Significant Response to the Combination of Lenvatinib and Immune Checkpoint Inhibitor in a Patient With Heavily Pretreated Metastatic Triple Negative Breast Cancer
por: Lee, Jin Sun, et al.
Publicado: (2021) -
Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancer
por: Lee, Kyoungmin, et al.
Publicado: (2023) -
Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients
por: Niu, Jiaxin, et al.
Publicado: (2015)